These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25882061)

  • 1. Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer.
    Stuchbery R; Kurganovs NJ; McCoy PJ; Nelson CC; Hayes VM; Corcoran NM; Hovens CM
    Curr Cancer Drug Targets; 2015; 15(5):394-405. PubMed ID: 25882061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Horizon scanning for novel therapeutics for the treatment of prostate cancer.
    Bianchini D; Zivi A; Sandhu S; de Bono JS
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1487-502. PubMed ID: 20868208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle therapeutics for prostate cancer treatment.
    Sanna V; Sechi M
    Nanomedicine; 2012 Sep; 8 Suppl 1():S31-6. PubMed ID: 22640911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review.
    Bhosale RR; Gangadharappa HV; Hani U; Ali M Osmani R; Vaghela R; Kulkarni PK; Koganti VS
    Curr Drug Targets; 2017; 18(11):1233-1249. PubMed ID: 27296312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The promise of targeted therapy: cancer drugs become more specific.
    Segota E; Bukowski RM
    Cleve Clin J Med; 2004 Jul; 71(7):551-60. PubMed ID: 15320364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Roychowdhury S; Goswami S; Ippolito JE; Priceman SJ; Pritchard CC; Sfanos KS; Subudhi SK; Simons JW; Pienta KJ; Soule HR
    Prostate; 2017 Feb; 77(2):123-144. PubMed ID: 27679977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting prostate cancer stem cells.
    Crea F; Mathews LA; Farrar WL; Hurt EM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1105-13. PubMed ID: 19925394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel targets and approaches in advanced prostate cancer.
    Hadaschik BA; Sowery RD; Gleave ME
    Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting gene therapy for prostate cancer.
    Maitland NJ; Stanbridge LJ; Dussupt V
    Curr Pharm Des; 2004; 10(5):531-55. PubMed ID: 14965338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agents targeting prostate cancer bone metastasis.
    Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas.
    Klemke CD; Goerdt S; Schrama D; Becker JC
    J Dtsch Dermatol Ges; 2006 May; 4(5):395-406. PubMed ID: 16686607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting kallikrein-related peptidases in prostate cancer.
    Mavridis K; Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2014 Apr; 18(4):365-83. PubMed ID: 24571737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions.
    Lin J; Wang C; Kelly WK
    Semin Oncol; 2013 Jun; 40(3):393-401. PubMed ID: 23806502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments].
    Jochims C; Mazitschek U; Jäger D; Goldschmidt H
    Internist (Berl); 2006 Jun; 47(6):633-41. PubMed ID: 16767478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of resistance to targeted cancer therapeutics.
    Mellinghoff IK; Sawyers CL
    Pharmacogenomics; 2002 Sep; 3(5):603-23. PubMed ID: 12223047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic predictors of prostate cancer therapy outcomes.
    Lewinshtein DJ; Porter CR; Nelson PS
    Expert Rev Mol Diagn; 2010 Jul; 10(5):619-36. PubMed ID: 20629511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the microRNA-regulating DNA damage/repair pathways in cancer.
    Bottai G; Pasculli B; Calin GA; Santarpia L
    Expert Opin Biol Ther; 2014 Nov; 14(11):1667-83. PubMed ID: 25190496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetable mutations found in metastatic prostate cancer.
    Balakrishnan VS
    Lancet Oncol; 2015 Jul; 16(7):e316. PubMed ID: 26040853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.